Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
J Korean Cancer Assoc. 1997 Jun;29(3):367-374. Korean. Original Article.
Han SU , Lee JH , Kim WH , Wang HJ , Cho YK , Kim MW .
Department of Surgery, Ajou University School of Medicine, Korea.
Department of Biochemistry, Ajou University School of Medicine, Korea.
Abstract

PURPOSE: Hepatocyte growth factor (HGF) is a modulator of epithelial cell proliferation and motility. In this study, we measured the level of HGF in sera and tumor extracts of gastric adenocarcinoma using an enzyme-linked immunoassay and evaluated its association with tumor progression. MATERIALS AND METHODS: The level of HGF in the sera of seventy-five patients with gastric adenocarcinoma and in the tumor extracts of forty-two tumors were examined in this study. The level of HGF was determined by an Immunis HGF EIA kit (Institute of Immunology). RESULTS: The mean level of HGF in the sera of patients was 0.26+/-0.19 ng/ml, which was significantly higher than in those of healthy controls (0.14+/-0.07 ng/ml, p<0.05); the levels of HGF in the sera of patients increased according to the progression of the stage of cancer (p<0.05). The mean level of HGF in tumor extracts was 8.22+/-9.27 microgram/g protein, which was significantly higher than in those of healthy controls (1.95+/-1.45 microgram/g protein, p<0.05); the levels of HGF in the tumor extracts were correlated significantly with the progression of the tumor stage (p<0.05). The mean level of HGF in the tumors of diffuse type was 11.28+/-11.74 microgram/g protein, which was significantly higher than in those of intestinal type (5.16+/-4.31 microgram/g protein, p<0.05). CONCLUSION: HGF may play an important role in the progression and differentiation of gastric adenocarcinoma.

Copyright © 2019. Korean Association of Medical Journal Editors.